Alterity Therapeutics Phase 2 Data Monitoring Committee

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26,...

Related Keywords

Melbourne ,Victoria ,Australia ,San Francisco ,California ,United States ,David Stamler ,Remy Bernarda ,Hannah Howlett ,Drug Administration ,European Commission ,Data Monitoring Committee ,Alterity Therapeutics ,Nasdaq ,Complete Enrollment ,Line Data Expected ,Chief Executive Officer ,Multiple System Atrophy ,System Atrophy ,Media Contacts ,Securities Act ,